BRPI1002601A2 - produto e processo de preparo e de nanocápsulas poliméricas caracterizadas contendo cloxacilina aplicáveis ao tratamento da mastite bovina - Google Patents

produto e processo de preparo e de nanocápsulas poliméricas caracterizadas contendo cloxacilina aplicáveis ao tratamento da mastite bovina Download PDF

Info

Publication number
BRPI1002601A2
BRPI1002601A2 BRPI1002601-0A BRPI1002601A BRPI1002601A2 BR PI1002601 A2 BRPI1002601 A2 BR PI1002601A2 BR PI1002601 A BRPI1002601 A BR PI1002601A BR PI1002601 A2 BRPI1002601 A2 BR PI1002601A2
Authority
BR
Brazil
Prior art keywords
cloxacillin
treatment
applicable
mastitis
drug
Prior art date
Application number
BRPI1002601-0A
Other languages
English (en)
Inventor
Carla Furtado Mosqueira Vanessa
Silva Araújo Raquel
De Mello Brandão Humberto
Original Assignee
Universidade Federal De Ouro Preto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De Ouro Preto filed Critical Universidade Federal De Ouro Preto
Priority to BRC11002601A priority Critical patent/BRPI1002601E2/pt
Priority to EP11788996.4A priority patent/EP2578209B1/en
Priority to PCT/BR2011/000168 priority patent/WO2011150481A1/pt
Priority to NZ74075611A priority patent/NZ740756A/en
Priority to US13/700,963 priority patent/US10098840B2/en
Priority to CN201180037401.9A priority patent/CN103118670B/zh
Priority to ARP110101895A priority patent/AR083628A1/es
Priority to AU2011261098A priority patent/AU2011261098A1/en
Publication of BRPI1002601A2 publication Critical patent/BRPI1002601A2/pt
Priority to AU2016204869A priority patent/AU2016204869A1/en
Priority to AU2018200535A priority patent/AU2018200535B2/en
Publication of BRPI1002601B1 publication Critical patent/BRPI1002601B1/pt
Publication of BRPI1002601E2 publication Critical patent/BRPI1002601E2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PRODUTO E PROCESSO DE PREPARO E DE NANOCáPSULAS POLIMéRICAS CARACTERIZADAS CONTENDO CLOXACILINA BENZATINA APLICáVEIS AO TRATAMENTO DA MASTITE BOVINA. A presente invenção refere-se ao desenvolvimento de dois tipos de nanocápsulas poliméricas as quais encapsularão o fármaco antimicrobiano cloxacilina benzatina. Mais especificamente esta invenção trata de uma nova forma de tratamento para a mastite em gado leiteiro. Foram desenvolvidas duas formulações de nanocápsulas que, poderão ser utilizadas para encapsular diferentes fármacos, além de encapsular o fármaco cloxacilina benzatina objetivando uma nova terapia para a mastite em vacas, contornando o inconveniente do emprego de altas doses de fármaco empregadas nas formulações tradicionais, contribuindo para a melhora da qualidade do leite.
BRC11002601A 2010-06-01 2010-06-01 composição nanoestruturada de uso veterinário para administração de fármacos BRPI1002601E2 (pt)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRC11002601A BRPI1002601E2 (pt) 2010-06-01 2010-06-01 composição nanoestruturada de uso veterinário para administração de fármacos
CN201180037401.9A CN103118670B (zh) 2010-06-01 2011-06-01 用于动物乳房内施用的含抗生素的纳米颗粒组合物
PCT/BR2011/000168 WO2011150481A1 (pt) 2010-06-01 2011-06-01 Composição nanoparticulada contendo antibióticos para administração intramamária de uso animal
NZ74075611A NZ740756A (en) 2010-06-01 2011-06-01 Nanoparticulate composition containing antibiotics for intramammary administration in animals
US13/700,963 US10098840B2 (en) 2010-06-01 2011-06-01 Nanoparticulate composition containing antibiotics for intramammary administration in animals
EP11788996.4A EP2578209B1 (en) 2010-06-01 2011-06-01 Nanoparticulate composition containing antibiotics for intramammary administration in animals
ARP110101895A AR083628A1 (es) 2010-06-01 2011-06-01 Composicion nanoparticulada que contiene antibioticos para administracion intramamaria de uso animal
AU2011261098A AU2011261098A1 (en) 2010-06-01 2011-06-01 Nanoparticulate composition containing antibiotics for intramammary administration in animals
AU2016204869A AU2016204869A1 (en) 2010-06-01 2016-07-12 Nanoparticle composition containing antibiotics for intramammary administration in animals
AU2018200535A AU2018200535B2 (en) 2010-06-01 2018-01-23 Nanoparticulate composition containing antibiotics for intramammary administration in animals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRC11002601A BRPI1002601E2 (pt) 2010-06-01 2010-06-01 composição nanoestruturada de uso veterinário para administração de fármacos

Publications (3)

Publication Number Publication Date
BRPI1002601A2 true BRPI1002601A2 (pt) 2012-03-13
BRPI1002601B1 BRPI1002601B1 (pt) 2020-02-11
BRPI1002601E2 BRPI1002601E2 (pt) 2020-06-30

Family

ID=45066077

Family Applications (1)

Application Number Title Priority Date Filing Date
BRC11002601A BRPI1002601E2 (pt) 2010-06-01 2010-06-01 composição nanoestruturada de uso veterinário para administração de fármacos

Country Status (7)

Country Link
US (1) US10098840B2 (pt)
EP (1) EP2578209B1 (pt)
CN (1) CN103118670B (pt)
AR (1) AR083628A1 (pt)
AU (3) AU2011261098A1 (pt)
BR (1) BRPI1002601E2 (pt)
WO (1) WO2011150481A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116570556A (zh) * 2023-05-17 2023-08-11 郑州福源动物药业有限公司 一种用于治疗畜禽大肠埃希菌和巴氏杆菌感染的复方磺胺氯达嗪钠溶液及其制备方法

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013129944A1 (en) 2012-02-27 2013-09-06 Bayer New Zealand Limited Controlled release compositions and their methods of use
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
BR102012022036B1 (pt) * 2012-08-31 2019-10-01 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso
PT106679B (pt) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2662300C2 (ru) * 2013-02-08 2018-07-25 Луода Фарма Пти Лимитед Способы лечения микробных инфекций, в том числе мастита
EP2953623B1 (en) * 2013-02-08 2021-06-30 Luoda Pharma Limited Methods of treating topical microbial infections
JP6396333B2 (ja) 2013-02-12 2018-09-26 ベンド・リサーチ・インコーポレーテッドＢｅｎｄ Ｒｅｓｅａｒｃｈ，Ｉｎｃｏｒｐｏｒａｔｅｄ 低水溶性活性物質の固体分散体
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
CN103222978B (zh) * 2013-04-02 2018-03-06 河南省乘风动物保健技术研究所 复方磺胺甲噁唑注射液及制备方法
PL3103351T3 (pl) * 2014-01-31 2019-04-30 Morishita Jintan Co Środek dla przeżuwaczy do podawania doustnego i zawierająca go pasza dla przeżuwaczy
US9468626B2 (en) * 2014-03-13 2016-10-18 Chiesi Farmaceutici S.P.A. Melatonin-based formulations for parenteral administration
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
JP6666858B2 (ja) 2014-06-11 2020-03-18 マサチューセッツ インスティテュート オブ テクノロジー 滞留構造体および関連方法
CN104060401A (zh) * 2014-07-04 2014-09-24 东华大学 一种释放维生素a的明胶纳米纤维膜的静电纺制备方法
EP3171864B1 (en) * 2014-07-25 2020-11-25 Bend Research, Inc Nanoparticle formulations of low-water solubility actives
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
CN105394045B (zh) * 2014-09-04 2020-02-14 中国科学院上海巴斯德研究所 一种肠道病毒的小分子化合物抑制剂及其应用
CN104188964B (zh) * 2014-09-11 2016-07-13 保定冀中药业有限公司 一种长效苄星氯唑西林乳房注入剂及其制备方法
MX385843B (es) 2014-09-12 2025-03-18 Antibiotx Aps Uso antibacteriano de salicilanilidas halogenadas.
CN104398510B (zh) * 2014-11-03 2016-09-07 郑州百瑞动物药业有限公司 一种奶牛用苄星氯唑西林乳房注入剂及其制备方法
CN104324036A (zh) * 2014-11-04 2015-02-04 重庆泰通动物药业有限公司 一种注射用磺胺间甲氧嘧啶钠的药物组合物
WO2016135075A1 (en) * 2015-02-23 2016-09-01 Sandoz Ag Penicillin retard composition for intramuscular injection
CN104800220B (zh) * 2015-03-11 2017-03-29 四川成康动物药业有限公司 一种用于解除体内细菌内毒素的药物组方
BR112017022768B1 (pt) 2015-04-24 2022-05-17 Sanuwave, Inc Aplicador de onda de choque de pressão acústica
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN105941308B (zh) * 2016-05-06 2018-08-17 中国医学科学院医学生物学研究所 一种通过药物净化和筛选法培育清洁级实验树鼩的方法
CN105997857A (zh) * 2016-06-29 2016-10-12 冯志清 一种用于治疗猪乳房炎的注射液
IL308091B1 (en) 2016-09-13 2026-01-01 Allergan Inc Protein-free stabilized Clostridium toxin preparations
PL3548001T3 (pl) * 2016-11-30 2022-07-11 Dukebox Sp. Z O.O. Sposób wytwarzania roztworu nanocząstek kwasu acetylosalicylowego albo diosminy albo drotaweryny
CN106667898B (zh) * 2017-02-22 2020-12-22 佛山市南海东方澳龙制药有限公司 癸氧喹酯制剂及其制备方法和应用
CN109528686A (zh) * 2017-09-22 2019-03-29 杭州景杰生物科技有限公司 利用微混合和卡培他滨两亲性质的卡培他滨的聚合物-脂质混合纳米颗粒
CN108403659A (zh) * 2018-03-01 2018-08-17 中国科学院过程工程研究所 一种硬乳液纳微球及其制备方法和应用
CN109320925B (zh) * 2018-09-29 2021-04-09 浙江和也健康科技有限公司 一种纳米抗菌母粒及其制备方法
CN109535720B (zh) * 2018-10-30 2021-02-09 武汉市科达云石护理材料有限公司 一种苯乙烯挥发抑制剂及其应用
CN109432092B (zh) * 2018-12-07 2020-06-09 中国农业科学院饲料研究所 一种泌乳期复方抗菌制剂及其制备方法与应用
CN109498577A (zh) * 2018-12-24 2019-03-22 宜昌三峡制药有限公司 易溶性复方磺胺氯达嗪钠粉
RU2711643C1 (ru) * 2019-01-10 2020-01-17 Федеральное государственное бюджетное образовательное учреждение высшего образования "Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО УГМУ Минздрава России) Противомикробная и ранозаживляющая лекарственная форма (варианты) и способ ее получения
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
CN110006724B (zh) * 2019-04-17 2021-06-04 郑州安图生物工程股份有限公司 采用巴氏和革兰氏染色方法检测滴虫用试剂
CN111249298B (zh) * 2020-04-08 2021-03-12 曲阜师范大学 一种含有马杜霉素和顺铂的抗癌药物组合物
CN112958285B (zh) * 2021-02-01 2022-08-05 核工业北京化工冶金研究院 一种用于贝塔石浮选的复配辅助捕收剂及其应用
CN112999330B (zh) * 2021-03-18 2023-04-18 成都大学 苯甲酸雌二醇与缩宫素长效混悬注射液的制备方法
US12240414B2 (en) 2022-01-06 2025-03-04 Ford Global Technologies, Llc Vehicle sensor control for optimized monitoring of preferred objects within a vehicle passenger cabin
CN116421731B (zh) * 2023-04-07 2025-09-23 佛山市南海东方澳龙制药有限公司 用于防治奶牛乳房炎的药物组合物及其制备方法
CN119454665A (zh) * 2025-01-16 2025-02-18 宁波科瑞特动物药业有限公司 一种基于高分子包埋技术的成膜型奶牛乳头抗菌药剂、使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621484D0 (en) * 1986-09-05 1986-10-15 Norbrook Lab Ltd Intramammary infusion
DE69529054T2 (de) * 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
IT1298575B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US7901711B1 (en) * 2006-04-17 2011-03-08 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
KR100718329B1 (ko) * 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
ATE515260T1 (de) * 2006-03-13 2011-07-15 Advanced In Vitro Cell Technologies S L Stabile nanokapselsysteme für die verabreichung von wirkstoffen
RU2508093C2 (ru) * 2008-07-01 2014-02-27 Нитто Денко Корпорейшн Фармацевтическая композиция, содержащая микрочастицы с поверхностным покрытием

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116570556A (zh) * 2023-05-17 2023-08-11 郑州福源动物药业有限公司 一种用于治疗畜禽大肠埃希菌和巴氏杆菌感染的复方磺胺氯达嗪钠溶液及其制备方法
CN116570556B (zh) * 2023-05-17 2023-11-07 郑州福源动物药业有限公司 一种用于治疗畜禽大肠埃希菌和巴氏杆菌感染的复方磺胺氯达嗪钠溶液及其制备方法

Also Published As

Publication number Publication date
EP2578209B1 (en) 2019-08-07
AU2011261098A1 (en) 2013-01-24
BRPI1002601B1 (pt) 2020-02-11
US20130189368A1 (en) 2013-07-25
AU2016204869A1 (en) 2016-07-28
US10098840B2 (en) 2018-10-16
EP2578209A4 (en) 2014-10-29
WO2011150481A1 (pt) 2011-12-08
AR083628A1 (es) 2013-03-13
AU2018200535B2 (en) 2019-09-05
EP2578209A1 (en) 2013-04-10
AU2018200535A1 (en) 2018-02-15
CN103118670B (zh) 2021-12-14
CN103118670A (zh) 2013-05-22
BRPI1002601E2 (pt) 2020-06-30

Similar Documents

Publication Publication Date Title
BRPI1002601A2 (pt) produto e processo de preparo e de nanocápsulas poliméricas caracterizadas contendo cloxacilina aplicáveis ao tratamento da mastite bovina
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
BR112017014649A2 (pt) ?isolado intestinal humano, e, composição?
BR112015028692A8 (pt) agente preventivo ou terapêutico para mastite de animal ruminante
JP2016521289A5 (pt)
JP2018521007A5 (pt)
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
BR112015027636A2 (pt) Uso da composição farmacêutica
Behan et al. Nutritional and health beneficial application of lactoferrin in some animal species: an updated review
RU2015125646A (ru) Вакцина против внутриутробного заболевания
CN103768025B (zh) 氟苯尼考琥珀酸钠可溶性粉及其制备方法和应用
MX2019002386A (es) Uso de oligosacaridos de leche humana en el engorde de terneros.
CN107929327B (zh) 一种提高牛蟾颗粒稳定性的制作工艺
CN104055836A (zh) 皮肤滋养抑菌乳膏
CN104814958B (zh) 一种含有阿莫西林的水溶性包被颗粒剂及其制备方法
NZ740756A (en) Nanoparticulate composition containing antibiotics for intramammary administration in animals
Khan et al. Exploration of antioxidant and antimicrobial potential of prunus dulcis and arachis hypogaea shells extracts
CN103610648B (zh) 一种恩诺沙星复合缓释微球的制备方法
CN107319134B (zh) 一种提高动物繁殖性能和抗病能力的饲料添加剂及制备方法
RU2629203C2 (ru) Антигельминтное средство для лечения и профилактики делафондиоза, альфортиоза, оксиуроза, стронгилеза и трихонематидозов лошадей
CN102988283A (zh) 一种土霉素注射液及其制备方法
CN104055782A (zh) 皮肤抑菌滋养乳膏
CN106727335A (zh) 一种乳酸环丙沙星可溶性粉及其制备方法
Maisa A et al. Therapeutic effect of lauric acid, a medium chain saturated fatty acid on giardia lamblia in experimentally infected hamsters
CN103585163A (zh) 一种治疗鸡球虫病的兽药

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/06/2010, OBSERVADAS AS CONDICOES LEGAIS.

B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B04C Request for examination: application reinstated [chapter 4.3 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL